Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment.

Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I

The Journal of clinical endocrinology and metabolism1 Feb 1995Cited by 89 (Europe PMC)

PMID7852533DOI10.1210/jcem.80.2.7852533PepBankPUB-07852533

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, GH increased left ventricular performance at 6 months and more at 12 months.
In plain wordsIn adults with hypopituitarism, left ventricular performance increased during GH treatment at 6 and 12 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft ventricular performance
Study
n = 10
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 6 and 12 monthsAs given in this study (human).
Source sentences
Summary
GH administration markedly increased left ventricular performance and reversed diastolic abnormalities at 6 and even more so at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253301
02HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, GH reversed diastolic abnormalities at 6 months and more at 12 months.
In plain wordsIn adults with hypopituitarism, diastolic abnormalities decreased during GH treatment at 6 and 12 months.
Peptide
HGH (somatotropin)
Outcome
DecreaseDiastolic abnormalities
Study
n = 10
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 6 and 12 monthsAs given in this study (human).
Source sentences
Summary
GH administration markedly increased left ventricular performance and reversed diastolic abnormalities at 6 and even more so at 12 months.
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253302
03HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, left ventricular mass increased after 12 months of GH versus pretreatment (P < 0.01).
In plain wordsIn adults with hypopituitarism, left ventricular mass increased from pretreatment after 12 months of GH.
Peptide
HGH (somatotropin)
Outcome
IncreaseLeft ventricular mass at 12 months
Study
n = 10
Comparator
Pretreatment values
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 12 monthsAs given in this study (human).
Source sentences
Summary
On the other hand, a clear increase in left ventricular mass was seen after 12, but not after 6, months of GH administration (P < 0.01 vs. pretreatment values).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253303
04HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, no clear increase in left ventricular mass was seen after 6 months of GH.
In plain wordsIn adults with hypopituitarism, no clear increase in left ventricular mass occurred after 6 months of GH.
Peptide
HGH (somatotropin)
Outcome
No significant changeLeft ventricular mass at 6 months
Study
n = 10
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 6 monthsAs given in this study (human).
Source sentences
Summary
On the other hand, a clear increase in left ventricular mass was seen after 12, but not after 6, months of GH administration (P < 0.01 vs. pretreatment values).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253304
05HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, increased left ventricular mass remained detectable 3 months after GH withdrawal versus pretreatment (P < 0.05).
In plain wordsIn adults with hypopituitarism, left ventricular mass remained above pretreatment 3 months after GH withdrawal.
Peptide
HGH (somatotropin)
Outcome
IncreasePersistence of left ventricular mass after withdrawal
Study
n = 10
Comparator
Pretreatment values
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 1 yr, followed by 3 months withdrawalAs given in this study (human).
Source sentences
Summary
In addition, although all changes induced by GH treatment disappeared within 3 months after GH withdrawal, at that time the increase in left ventricular mass was still detectable (P < 0.05 vs. pretreatment values).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253305
06HumanNon-randomized trialEfficacy outcome
In adults with hypopituitarism, other GH-induced cardiac changes disappeared within 3 months after GH withdrawal.
In plain wordsIn adults with hypopituitarism, other cardiac changes disappeared within 3 months after GH withdrawal.
Peptide
HGH (somatotropin)
Outcome
No significant changePersistence of other cardiac changes after withdrawal
Study
n = 10
Outcome group
Heart function · Cardiovascular
Studied dose
0.05 U/kg.day, 0.03 U/kg.day first month · 1 yr, followed by 3 months withdrawalAs given in this study (human).
Source sentences
Summary
In addition, although all changes induced by GH treatment disappeared within 3 months after GH withdrawal, at that time the increase in left ventricular mass was still detectable (P < 0.05 vs. pretreatment values).
2 context sentences(design, population, supporting numbers)
Summary · context
We studied the effects of GH administration on myocardial structure and function in 20 patients with hypopituitarism (14 males and 6 females; mean +/- SE age, 47.2 +/- 2.6 yr; range, 31-59 yr) developed in adulthood because of pituitary or parapituitary tumors.
Summary · context
Patients received either placebo (n = 10) or GH substitution therapy (n = 10; 0.05 U/kg.day GH for 1 yr; 0.03 U/kg.day during the first month).
Report a problemFND-0785253306

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.